YALE COMPREHENSIVE CANCER CENTER

耶鲁大学综合癌症中心

• 批准号: 8533307
• 负责人: Thomas James Lynch
• 金额: $ 7.5万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-07-01 至 2013-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8533307
• 关键词: Antineoplastic Agents; Basic Science; Biological; Budgets; Cancer Center Support Grant; Clinical; Clinical Investigator; Clinical Research; Clinical Sciences; Clinical Trials; Comprehensive Cancer Center; Consultations; Development; Direct Costs; Disorder by Site; Faculty; Funding; Gene Expression Regulation; Guidelines; Laboratories; Malignant Neoplasms; Medical Oncology; Modality; Molecular Diagnosis; Peer Review; Protocols documentation; Radiation therapy; Receptor Protein-Tyrosine Kinases; Recruitment Activity; Research; Research Personnel; Research Project Grants; Research Support; Review Committee; Schools; Science; Scientist; Services; Signal Transduction; Stress; Structure; Translations; Yale Cancer Center; base; cancer therapy; cost; design; functional genomics; inhibitor/antagonist; member; programs; small molecule

The Yale Cancer Center (YCC) was designated as an NCI Comprehensive Cancer Center in 1974. YCC has elected to profoundly alter its structure to better facilitate clinical translation of its abundant scientific strengths. A particularly important component, taken in consultation with the NCI, was relocation of operational control of Medical Oncology to YCC, to augment Center influence over the Clinical Trials Program. An administrative 3-year extension from the NCI enabled these changes. The new Director, Richard Edelson, an accomplished translational scientist, has led the Center since these pivotal changes were initiated in 2003. Over $68 million of institutional support permitted YCC to enhance facilities and recruit 60 external faculty members, including leaders of 5 of the 8 Research Programs, 6 of the 11 interdisciplinary cancer disease site teams and both the Clinical Research Services Core and Protocol Review Committee. Strategic scientific recruitments include Joseph Schlesinger (pioneer in the design of inhibitors of receptor tyrosine kinases and now Co-Leader of the Signal Transduction Program) and Jeffrey Sklar (a leading innovator in molecular diagnosis of cancer and now Co-Leader of the Gene Regulation and Functional Genomics Program). Preserving continuity by reappointing the Deputy Director, the Director appointed new Associate Directors of Basic and Clinical Sciences. All Research Programs now thematically stress mechanistic themes, and the Clinical Division has been organized around the three main cancer treatment modalities (small molecules/anticancer agents, radiation therapy, and biological/ immunological agents), rather than being confined to single disease sites. Due to these collective YCC structural and functional changes, the number of investigator initiated clinical trials, based on YCC science, have dramatically increased. Construction has begun on a $460M new Clinical Cancer Tower, proximal to the YCC scientific laboratories. The 210 YCC members come from 27 Yale Departments and 4 Schools. Since the last CCSG submission, total peer-reviewed, annual direct costs of cancer-relevant research support increased by 42%, from $43 million to $62 million, inclusive of $15.3 million from the NCI. Integration of the new scientific and clinical investigators has permitted the YCC to target 8 sets of grouped research projects for focused development. Last approved in 1998, YCC continues to satisfy guidelines for Comprehensiveness. Based on the NCI total cost funding base of $25.6 million, YCC is requesting a budget of $3.8 million in total costs.

耶鲁大学癌症中心 (YCC) 于 1974 年被指定为 NCI 综合癌症中心。YCC 选择深刻改变其结构，以更好地促进其丰富的科学优势的临床转化。与 NCI 协商后采取的一个特别重要的组成部分是将肿瘤内科的运营控制权转移到 YCC，以增强中心对临床试验计划的影响力。 NCI 的行政延期 3 年促成了这些变化。自 2003 年启动这些关键变革以来，新任主任理查德·埃德尔森 (Richard Edelson) 一直领导着该中心。超过 6800 万美元的机构支持使 YCC 能够增强设施并招募 60 名外部教员，其中包括 8 个研究项目中的 5 个、11 个跨学科癌症疾病现场团队中的 6 个以及临床研究服务核心和方案审查委员会的领导者。战略性科学招聘包括约瑟夫·施莱辛格（Joseph Schlesinger）（受体酪氨酸激酶抑制剂设计的先驱，现任信号转导项目的联合负责人）和杰弗里·斯克拉（Jeffrey Sklar）（癌症分子诊断领域的领先创新者，现任基因调控和功能基因组学项目的联合负责人）。为了保持连续性，重新任命了副主任，主任任命了新的基础和临床科学副主任。现在所有研究项目都强调机械主题，临床部门围绕三种主要癌症治疗方式（小分子/抗癌药物、放射治疗和生物/免疫药物）进行组织，而不是局限于单一疾病部位。由于 YCC 结构和功能的这些集体变化，基于 YCC 科学的研究者发起的临床试验数量急剧增加。耗资 4.6 亿美元的新临床癌症塔已开始施工，该塔靠近 YCC 科学实验室。 YCC的210名成员来自耶鲁大学27个系和4个学院。自上次 CCSG 提交以来，癌症相关研究支持的同行评审年度直接成本总额增加了 42%，从 4300 万美元增加到 6200 万美元，其中包括来自 NCI 的 1530 万美元。新的科学和临床研究人员的整合使 YCC 能够针对 8 组分组研究项目进行重点开发。上次批准于 1998 年，YCC 继续满足综合性准则。 基于 NCI 2560 万美元的总成本资助基础，YCC 请求总成本为 380 万美元的预算。